NCT05734677 (EmoReg) is a NA clinical trial of Emotion regulation group in Emotional Dysfunction, sponsored by Camille Nemitz Piguet.

Who is sponsoring NCT05734677?

NCT05734677 is sponsored by Camille Nemitz Piguet.

What drugs are being tested in NCT05734677?

Interventions in NCT05734677: Emotion regulation group.

What condition does NCT05734677 study?

NCT05734677 studies Emotional Dysfunction, Borderline Personality Disorder.

Is NCT05734677 still recruiting?

NCT05734677 is currently status unknown. Last updated 21 February 2023.

Last reviewed 2023-02-21 · How we verify

NCT05734677: EmoReg

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Emotion Regulation Group Study

Status unknown NA Last updated 21 February 2023

What this trial tests

NA trial testing Emotion regulation group in Emotional Dysfunction in 56 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
6 September 2023

31 December 2023

Quick facts

Lead sponsor	Camille Nemitz Piguet
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	56
Start date	1 January 2022
Primary completion	6 September 2023
Estimated completion	31 December 2023
Sites	1 location across Switzerland

Drugs / interventions tested

Emotion regulation group

Conditions studied

Emotional Dysfunction — all drugs for Emotional Dysfunction →
Borderline Personality Disorder — all drugs for Borderline Personality Disorder →

Sponsor

Camille Nemitz Piguet

Who can join

Adults 16 to 20, any sex, with Emotional Dysfunction or Borderline Personality Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A clinical trial to evaluate the effects of an eight-week emotion regulation group intervention designed for adolescents (16-20 years old) on the levels of emotion dysregulation both self-reported by the adolescent and reported by his/her parent/caregiver (pre-post comparison). The long-term effect will also be measured at a third-time point, three months after the end of the intervention. The intervention will consist of 90-minute sessions once a week for 8 weeks, in groups of eight participants. The intervention proposed for this study is an adaptation from different interventions already in use for adolescents in clinical practice, such as Dialectical Behavior Therapy (DBT), Mentalization-Based Treatment (MBT) and Mindfulness-Based Intervention (MBI).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Emotional Dysfunction

Currently open trials in the same condition.

NCT05712057 — Neurostimulation Versus Therapy for Problems With Emotions · NA · recruiting
NCT05930886 — Focus Groups in Ethnically and Racially Diverse Families · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05734677 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Camille Nemitz Piguet
Last refreshed: 21 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05734677.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing